NGM Biopharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 25th, 2019 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • New York
NGM Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $0.001 per share (“Stock”), of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”.
NGM BIOPHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for David J. Woodhouse, Ph.D.Executive Employment Agreement • March 25th, 2019 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Employment Agreement (“Agreement”) is effective as of July 25, 2018, by and between David J. Woodhouse, Ph.D. (“Executive”) and NGM Biopharmaceuticals, Inc. (the “Company”).
CONFIDENTIALMulti-Product License Agreement • March 25th, 2019 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • New York
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
NGM BIOPHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Aetna Wun TrombleyExecutive Employment Agreement • March 25th, 2019 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Employment Agreement (“Agreement”) is effective as of July 25, 2018, by and between Aetna Wun Trombley (“Executive”) and NGM Biopharmaceuticals, Inc. (the “Company”).
